{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T02:54:56Z","timestamp":1777172096332,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Dongkook Pharma Co, Ltd"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ejca.2020.11.044","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T03:55:50Z","timestamp":1609386950000},"page":"341-350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Leuprorelin combined with letrozole with\/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study"],"prefix":"10.1016","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8749-2612","authenticated-orcid":false,"given":"Jae Ho","family":"Jeong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9766-1531","authenticated-orcid":false,"given":"Jeong Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Hee","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Hae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1545-8036","authenticated-orcid":false,"given":"Su-Jin","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaekyung","family":"Cheon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joohyuk","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gun Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keun Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Hoon","family":"Sim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In Hae","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Bae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.11.044_bib1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Canc J Clin"},{"issue":"69","key":"10.1016\/j.ejca.2020.11.044_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics","volume":"2019","author":"Siegel","year":"2019","journal-title":"CA Canc J Clin"},{"issue":"69","key":"10.1016\/j.ejca.2020.11.044_bib3","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3322\/caac.21583","article-title":"Breast cancer statistics","volume":"2019","author":"DeSantis","year":"2019","journal-title":"CA Canc J Clin"},{"key":"10.1016\/j.ejca.2020.11.044_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4048\/jbc.2018.21.1.1","article-title":"Basic findings regarding breast cancer in Korea in 2015: data from a breast cancer registry","volume":"21","author":"Kang","year":"2018","journal-title":"J Breast Canc"},{"key":"10.1016\/j.ejca.2020.11.044_bib5","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s13058-014-0427-5","article-title":"Biology of breast cancer in young women","volume":"16","author":"Azim","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2020.11.044_bib6","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/jnci\/djt134","article-title":"Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: the POSH study","volume":"105","author":"Copson","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2020.11.044_bib7","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO-ESMO International consensus guidelines for advanced breast cancer (ABC 4)dagger","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.11.044_bib8","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","article-title":"Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline","volume":"34","author":"Rugo","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.11.044_bib9","series-title":"NCCN clinical practice guidelines in oncology: breast cancer, version 4","year":"2020"},{"key":"10.1016\/j.ejca.2020.11.044_bib10","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1158\/1078-0432.CCR-18-0162","article-title":"Targeted therapy for premenopausal women with HR(+), HER2(\u2212) advanced breast cancer: focus on special considerations and latest advances","volume":"24","author":"Bardia","year":"2018","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2020.11.044_bib11","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.11.044_bib12","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.11.044_bib13","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.11.044_bib14","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial","author":"Sledge","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2020.11.044_bib15","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.11.044_bib16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.11.044_bib17","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.11.044_bib18","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S1470-2045(19)30565-0","article-title":"Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial","volume":"20","author":"Park","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.11.044_bib19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejca.2018.08.004","volume":"103","author":"Kim","year":"2018","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.11.044_bib20","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMra023246","article-title":"Aromatase inhibitors in breast cancer","volume":"348","author":"Smith","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.11.044_bib21","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1200\/JCO.2001.19.10.2596","article-title":"Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group","volume":"19","author":"Mouridsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.11.044_bib22","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2007.13.5822","article-title":"Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT","volume":"26","author":"Chia","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.11.044_bib23","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.11.044_bib24","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S1470-2045(17)30109-2","article-title":"Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial","volume":"18","author":"Rugo","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.11.044_bib25","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","article-title":"Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study","volume":"30","author":"Bachelot","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.11.044_bib26","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/jamaoncol.2018.0060","article-title":"Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a clinical trial","volume":"4","author":"Royce","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2020.11.044_bib27","article-title":"Abstract PD7-08: everolimus in first-line treatment of advanced premenopausal breast cancer: results from MIRACLE (everoliMus trIal foR AdvanCed premenopausaL brEast cancer) study","author":"Fan","year":"2020","journal-title":"AACR"},{"key":"10.1016\/j.ejca.2020.11.044_bib28","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.ejca.2013.04.011","article-title":"Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study","volume":"49","author":"Campone","year":"2013","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.11.044_bib29","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13058-015-0618-8","article-title":"The molecular landscape of premenopausal breast cancer","volume":"17","author":"Liao","year":"2015","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2020.11.044_bib30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4143\/crt.2011.43.2.89","article-title":"Implications of bone-only metastases in breast cancer: favorable preference with excellent outcomes of hormone receptor positive breast cancer","volume":"43","author":"Lee","year":"2011","journal-title":"Canc Res Treat"},{"key":"10.1016\/j.ejca.2020.11.044_bib31","author":"Gianni","year":"2018","journal-title":"AACR"}],"updated-by":[{"DOI":"10.1016\/j.ejca.2021.02.004","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000}}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920314106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920314106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T01:15:58Z","timestamp":1668734158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920314106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":31,"alternative-id":["S0959804920314106"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.11.044","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ejca.2021.02.004","asserted-by":"object"}]},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leuprorelin combined with letrozole with\/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.11.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}